Peter James Francis1. 1. Divisions of Retina and Ophthalmic Genetics, Casey Eye Institute, Oregon Health and Science University, Portland, OR, USA.
Abstract
PURPOSE: Age-related macular degeneration (AMD) has a complex etiology arising from genetic and environmental influences. This past decade have seen several genes associated with the disease. Variants in five genes have been confirmed to play a major role. The objective of this study was to evaluate whether genes influence treatment response to ranibizumab for neovascular AMD. The hypothesis was that an individual's genetic variation will determine treatment response. METHODS: The study was a two-site prospective open-label observational study of patients newly diagnosed with exudative (neovascular) AMD receiving intravitreal ranibizumab therapy. Treatment-naïve patients were enrolled at presentation and received monthly "as needed" therapy. Clinical data was collected monthly and DNA extracted. Genotyping was performed using the Illumina (San Diego, California) 660-Quad single-nucleotide polymorphism (SNP) chip. Regression analyses were performed to identify SNPs associated with treatment-response end points. RESULTS: Sixty-five patients were enrolled. No serious adverse events were recorded. The primary outcome measure was change in ETDRS visual acuity at 12 months. A SNP in the CFH gene was found to be associated with less improvement in visual acuity while receiving ranibizumab therapy. The C3 gene, among others, was associated with reduced thickening and improved retinal architecture. VEGFA, FLT1, and CFH were associated with requiring fewer ranibizumab injections over the 12-month study. CONCLUSIONS: This study is one of the first prospective pharmacogenetic study of intravitreal ranibizumab. Although preliminary, the results identify a number of putative genetic variants, which will be further examined by replication and functional studies to elucidate the complete pharmacogenetic architecture of therapy for AMD.
PURPOSE: Age-related macular degeneration (AMD) has a complex etiology arising from genetic and environmental influences. This past decade have seen several genes associated with the disease. Variants in five genes have been confirmed to play a major role. The objective of this study was to evaluate whether genes influence treatment response to ranibizumab for neovascular AMD. The hypothesis was that an individual's genetic variation will determine treatment response. METHODS: The study was a two-site prospective open-label observational study of patients newly diagnosed with exudative (neovascular) AMD receiving intravitreal ranibizumab therapy. Treatment-naïve patients were enrolled at presentation and received monthly "as needed" therapy. Clinical data was collected monthly and DNA extracted. Genotyping was performed using the Illumina (San Diego, California) 660-Quad single-nucleotide polymorphism (SNP) chip. Regression analyses were performed to identify SNPs associated with treatment-response end points. RESULTS: Sixty-five patients were enrolled. No serious adverse events were recorded. The primary outcome measure was change in ETDRS visual acuity at 12 months. A SNP in the CFH gene was found to be associated with less improvement in visual acuity while receiving ranibizumab therapy. The C3 gene, among others, was associated with reduced thickening and improved retinal architecture. VEGFA, FLT1, and CFH were associated with requiring fewer ranibizumab injections over the 12-month study. CONCLUSIONS: This study is one of the first prospective pharmacogenetic study of intravitreal ranibizumab. Although preliminary, the results identify a number of putative genetic variants, which will be further examined by replication and functional studies to elucidate the complete pharmacogenetic architecture of therapy for AMD.
Authors: Imran A Bhutto; D Scott McLeod; Takuya Hasegawa; Sahng Y Kim; Carol Merges; Patrick Tong; Gerard A Lutty Journal: Exp Eye Res Date: 2005-07-12 Impact factor: 3.467
Authors: Andrea Rivera; Sheila A Fisher; Lars G Fritsche; Claudia N Keilhauer; Peter Lichtner; Thomas Meitinger; Bernhard H F Weber Journal: Hum Mol Genet Date: 2005-09-20 Impact factor: 6.150
Authors: K Ohno-Matsui; I Morita; J Tombran-Tink; D Mrazek; M Onodera; T Uetama; M Hayano; S I Murota; M Mochizuki Journal: J Cell Physiol Date: 2001-12 Impact factor: 6.384
Authors: Jonathan L Haines; Nathalie Schnetz-Boutaud; Silke Schmidt; William K Scott; Anita Agarwal; Eric A Postel; Lana Olson; Shannon J Kenealy; Michael Hauser; John R Gilbert; Margaret A Pericak-Vance Journal: Invest Ophthalmol Vis Sci Date: 2006-01 Impact factor: 4.799
Authors: Andrew Grupe; Yonghong Li; Charles Rowland; Petra Nowotny; Anthony L Hinrichs; Scott Smemo; John S K Kauwe; Taylor J Maxwell; Sara Cherny; Lisa Doil; Kristina Tacey; Ryan van Luchene; Amanda Myers; Fabienne Wavrant-De Vrièze; Mona Kaleem; Paul Hollingworth; Luke Jehu; Catherine Foy; Nicola Archer; Gillian Hamilton; Peter Holmans; Chris M Morris; Joseph Catanese; John Sninsky; Thomas J White; John Powell; John Hardy; Michael O'Donovan; Simon Lovestone; Lesley Jones; John C Morris; Leon Thal; Michael Owen; Julie Williams; Alison Goate Journal: Am J Hum Genet Date: 2005-11-15 Impact factor: 11.025
Authors: W M Amoaku; U Chakravarthy; R Gale; M Gavin; F Ghanchi; J Gibson; S Harding; R L Johnston; S P Kelly; S Kelly; A Lotery; S Mahmood; G Menon; S Sivaprasad; J Talks; A Tufail; Y Yang Journal: Eye (Lond) Date: 2015-04-17 Impact factor: 3.775
Authors: Leah A Owen; Margaux A Morrison; Jeeyun Ahn; Se Joon Woo; Hajime Sato; Rosann Robinson; Denise J Morgan; Fani Zacharaki; Marina Simeonova; Hironori Uehara; Usha Chakravarthy; Ruth E Hogg; Balamurali K Ambati; Maria Kotoula; Wolfgang Baehr; Neena B Haider; Giuliana Silvestri; Joan W Miller; Evangelia E Tsironi; Lindsay A Farrer; Ivana K Kim; Kyu Hyung Park; Margaret M DeAngelis Journal: Invest Ophthalmol Vis Sci Date: 2014-05-08 Impact factor: 4.799
Authors: Stephanie A Hagstrom; Gui-Shuang Ying; Gayle J T Pauer; Gwen M Sturgill-Short; Jiayan Huang; David G Callanan; Ivana K Kim; Michael L Klein; Maureen G Maguire; Daniel F Martin Journal: Ophthalmology Date: 2013-01-18 Impact factor: 12.079
Authors: Anjali R Shah; Steven Williams; Caroline R Baumal; Bernard Rosner; Jay S Duker; Johanna M Seddon Journal: Am J Ophthalmol Date: 2015-12-15 Impact factor: 5.258
Authors: Hironori Uehara; Christina Mamalis; Molly McFadden; Michael Taggart; Brian Stagg; Samuel Passi; Phillip Earle; Usha Chakravarthy; Ruth E Hogg; Balamurali K Ambati Journal: Am J Ophthalmol Date: 2014-10-18 Impact factor: 5.258